Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MMP14 | P50281 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25257294 | 0.77 | CHEK1 (0.39) | DAOCHEK1FLT3PLK3KDM4E | |
| SCHEMBL30423773 | 0.77 | CHEK1 (0.39) | DAOCHEK1FLT3PLK3KDM4E | |
| SCHEMBL28380264 | 0.71 | MAPK1 (0.48) | DAOKDM4EMEN1KMT2ATDP1 | |
| SCHEMBL30424722 | 0.69 | LRRK2 (0.41) | DAOCHEK1AXLPRKCI | |
| SCHEMBL15799693 | 0.69 | LRRK2 (0.41) | DAOCHEK1AXLPRKCI | |
| SCHEMBL6851931 | 0.67 | MAPT (0.40) | KDM4EALDH1A1LMNAMAPTHTT | |
| SCHEMBL29361454 | 0.67 | CHEK1 (0.63) | DAOCHEK1FLT3PLK3CYP1A2 | |
| SCHEMBL7014902 | 0.66 | NR4A2 (0.48) | DAOKDM4EMEN1KMT2ATDP1 | |
| SCHEMBL14906033 | 0.64 | MAPK1 (0.45) | MAPK1 | |
| SCHEMBL30548007 | 0.64 | HTR2A (0.35) | CHEK1FLT3PLK3CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522598-B2 | 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as HDAC6 inhibitors | ORYZON GENOMICS SA (ES) | 2026-01-13 | — | — | US | disclosed |
| CN-114206868-B | 3- (2- (Heteroaryl) -pyridin-4-yl) -5- (trifluoromethyl) -1,2, 4-oxadiazole derivatives as HDAC6 inhibitors | 奥莱松基因组股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20220298156-A1 | 3-(2-(HETEROARYL)-PYRIDIN-4-YL)-5-(TRIFLUOROMETHYL)-1,2,4-OXADIAZOLE DERIVATIVES AS HDAC6 INHIBITORS | ORYZON GENOMICS SA (ES) | 2022-09-22 | — | — | US | disclosed |
| CN-114206868-A | 3- (2- (heteroaryl) -pyridin-4-yl) -5- (trifluoromethyl) -1,2, 4-oxadiazole derivatives as HDAC6 inhibitors | 奥莱松基因组股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2020245381-A1 | 3-(2-(HETEROARYL)-PYRIDIN-4-YL)-5-(TRIFLUOROMETHYL)-1,2,4-OXADIAZOLE DERIVATIVES AS HDAC6 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2020-12-10 | — | — | WO | disclosed |
| US-7652035-B2 | CRF receptor antagonists and methods relating thereto | Neurocrine Bioscience, Inc. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1802621-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SMITHKLINE BEECHAM CORK LTD (IE) | 2009-05-06 | — | — | EP | disclosed |
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-03-13 | — | — | US | disclosed |
| EP-1802621-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SB Pharmco Puerto Rico Inc. (PR) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044821-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SB PHARMCO PUERTO RICO INC. (PR) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | CRHR1, CRHR2, SCTR | DAO 673/4885CHEK1 4302/4885FLT3 3091/4885 |
| US-20220298156-A1 | 3-(2-(HETEROARYL)-PYRIDIN-4-YL)-5-(TRIFLUOROMETHYL)-1,2,4-OXADIAZOLE DERIVATIVES AS HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | DAO 3781/4885CHEK1 2418/4885FLT3 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.